A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Stopped early · Not applicable

Conditions studied: Solid Tumors

In brief

Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).

Key facts

Study ID

NCT01369433

Run by

AVEO Pharmaceuticals, Inc.

People needed

225

Starts

2010-06-01

Expected to finish

2015-10-01

Last updated by the study team

2020-09-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject must have received tivozanib while enrolled in another protocol, must be tolerating study drug and must currently display clinical benefit. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the parent protocol.
• If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
• Ability to give written informed consent.

You may not qualify if…

• > 4 weeks since discontinuation of tivozanib treatment on a previous protocol
• If female, pregnant or lactating
• Sexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Highly effective birth control includes (a) intrauterine device plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
• Uncontrolled hypertension: systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.
• Newly identified central nervous system (CNS) malignancies or documented progression of CNS metastases; subjects will be allowed only if the CNS metastases have been adequately treated with radiotherapy or surgery. For subjects receiving steroid therapy please refer to Section 6.3 for allowed steroid maintenance therapy.
• Unhealed wounds (including active peptic ulcers)
• Serious/active infection or infection requiring parenteral antibiotics
• Life-threatening illness or organ system dysfunction compromising safety evaluation
• Psychiatric disorder, altered mental status precluding informed consent or necessary testing
• Inability to comply with protocol requirements

Where it is running

• Translational Genomics Research Institute (TGEN) — Scottsdale, Arizona, United States
• Institute of Urologic Oncology — Los Angeles, California, United States
• Stanford University — Stanford, California, United States
• Study site — Aurora, Colorado, United States
• Florida Cancer Specialists — Fort Myers, Florida, United States
• H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc — Tampa, Florida, United States
• Study site — Beech Grove, Indiana, United States
• Horizon Oncology Research, Inc. — Lafayette, Indiana, United States
• Study site — Wichita, Kansas, United States
• Medical Oncology LLC — Baton Rouge, Louisiana, United States
• Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC — Metairie, Louisiana, United States
• Associates in Oncology/Hematology — Rockville, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Tupelo, Mississippi, United States
• Nebraska Methodist Hospital — Omaha, Nebraska, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Columbus, Ohio, United States
• The OU Cancer Institute — Oklahoma City, Oklahoma, United States
• Study site — Philadelphia, Pennsylvania, United States
• Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee, United States
• Study site — Austin, Texas, United States
• Coastal Bend Cancer Center — Corpus Christi, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.